The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Subcutaneous Alemtuzumab in Fludarabine-Refractory Chronic Lymphocytic Leukemia: Clinical Results and Prognostic Marker Analyses From the CLL2H Study of the German Chronic Lymphocytic Leukemia Study Group
Open accessAbstract
Purpose: The phase II CLL2H trial evaluated safety and efficacy of subcutaneous alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia (CLL). Clinical and biologic markers were evaluated for their impacts on outcome. Patients and Methods: One hundred nine patients were enrolled, and 103 received at least one dose of alemtuzumab. After dose escalation, alemtuzumab was administered subcutaneously at 30 mg three times weekly for up to 12 weeks. Response was assessed every 4 weeks during treatment and quarterly thereafter. Results: The overall response rate was 34% (complete response, 4%; partial response, 30%). The median progression-free survival was 7.7 months, and the median overall survival (OS) was 19.1 months. Grades 3 to 4 neutropenia, thrombocytopenia, and anemia occurred in 56%, 57%, and 49% of patients, respectively. Grades 3 to 4 noncytomegalovirus and cytomegalovirus infections occurred in 29% and 8% of patients, respectively. Injection-site skin reactions were generally mild. Efficacy did not vary significantly in subgroups defined by genetic parameters (in particular, in 17p deletion, 11q deletion, mutated TP53, and unmutated VH), but efficacy was inferior in patients with increased β2-microglobulin (β2-MG) and thymidine kinase (TK). In multivariate analysis of clinical and biologic variables, age, performance status, β2-MG, and TK were independent prognostic factors for OS. Conclusion: Subcutaneous alemtuzumab appears as effective and safe as intravenous alemtuzumab in fludarabine-refractory CLL. Subcutaneous administration should be the preferred delivery route because of its efficacy, convenience, improved adverse effect profile, and cost savings. In contrast to chemotherapy-based therapy, alemtuzumab treatment overcomes the adverse prognostic impact of VH mutation status, TP53 mutation, and genomic aberrations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
R: A Language and Environment for Statistical Computing
R Core Team (2025) · doi:10.32614/r.manuals · Cited by 352,181
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Harrell, F. E. (2001) · Springer Series in Statistics · doi:10.1007/978-1-4757-3462-1 · Cited by 9,195
Hallek, M., Cheson, B. D., Catovsky, D., Caligaris-Cappio, F., Dighiero, G., Döhner, H., Hillmen, P., Keating, M. J., Montserrat, E., Rai, K. R., et al. (2008) · Blood · doi:10.1182/blood-2007-06-093906 · Cited by 3,787
Self-citationGenomic Aberrations and Survival in Chronic Lymphocytic Leukemia
Döhner, H., Stilgenbauer, S., Benner, A., Leupolt, E., Kröber, A., Bullinger, L., Döhner, K., Bentz, M., & Lichter, P. (2000) · New England Journal of Medicine · doi:10.1056/nejm200012283432602 · Cited by 3,318
Self-citationThymocyte apoptosis induced by p53-dependent and independent pathways
Clarke, A. R., Purdie, C. A., Harrison, D. J., Morris, R. G., Bird, C. C., Hooper, M. L., & Wyllie, A. H. (1993) · Nature · doi:10.1038/362849a0 · Cited by 2,271
Cheson, B., Bennett, J., Grever, M., Kay, N., Keating, M., O'Brien, S., & Rai, K. (1996) · Blood · doi:10.1182/blood.v87.12.4990.bloodjournal87124990 · Cited by 1,819
Fludarabine Compared with Chlorambucil as Primary Therapy for Chronic Lymphocytic Leukemia
Rai, K. R., Peterson, B. L., Appelbaum, F. R., Kolitz, J., Elias, L., Shepherd, L., Hines, J., Threatte, G. A., Larson, R. A., Cheson, B. D., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200012143432402 · Cited by 1,001
Keating, M. J., O’Brien, S., Albitar, M., Lerner, S., Plunkett, W., Giles, F., Andreeff, M., Cortes, J., Faderl, S., Thomas, D., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.12.051 · Cited by 950
Keating, M. J., Flinn, I., Jain, V., Binet, J.-L., Hillmen, P., Byrd, J., Albitar, M., Brettman, L., Santabarbara, P., Wacker, B., et al. (2002) · Blood · doi:10.1182/blood.v99.10.3554 · Cited by 948
Kröber, A., Seiler, T., Benner, A., Bullinger, L., Brückle, E., Lichter, P., Döhner, H., & Stilgenbauer, S. (2002) · Blood · doi:10.1182/blood.v100.4.1410.h81602001410_1410_1416 · Cited by 785
Self-citationDohner, H., Fischer, K., Bentz, M., Hansen, K., Benner, A., Cabot, G., Diehl, D., Schlenk, R., Coy, J., Stilgenbauer, S., et al. (1995) · Blood · doi:10.1182/blood.v85.6.1580.bloodjournal8561580 · Cited by 732
Self-citationCatovsky, D., Richards, S., Matutes, E., Oscier, D., Dyer, M., Bezares, R., Pettitt, A., Hamblin, T., Milligan, D., Child, J., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61125-8 · Cited by 677
Maximally Selected Rank Statistics
Lausen, B., & Schumacher, M. (1992) · Biometrics · doi:10.2307/2532740 · Cited by 643
Loehrer, P. J. (2008) · Yearbook of Oncology · doi:10.1016/s1040-1741(08)79037-7 · Cited by 602
Eichhorst, B. F. (2005) · Blood · doi:10.1182/blood-2005-06-2395 · Cited by 588
Alemtuzumab Compared With Chlorambucil As First-Line Therapy for Chronic Lymphocytic Leukemia
Hillmen, P., Skotnicki, A. B., Robak, T., Jaksic, B., Dmoszynska, A., Wu, J., Sirard, C., & Mayer, J. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.9098 · Cited by 561
Lundin, J., Kimby, E., Björkholm, M., Broliden, P.-A., Celsing, F., Hjalmar, V., Möllgård, L., Rebello, P., Hale, G., Waldmann, H., et al. (2002) · Blood · doi:10.1182/blood-2002-01-0159 · Cited by 497
Chanan-Khan, A., Miller, K. C., Musial, L., Lawrence, D., Padmanabhan, S., Takeshita, K., Porter, C. W., Goodrich, D. W., Bernstein, Z. P., Wallace, P., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.0401 · Cited by 414
Flinn, I. W., Neuberg, D. S., Grever, M. R., Dewald, G. W., Bennett, J. M., Paietta, E. M., Hussein, M. A., Appelbaum, F. R., Larson, R. A., Moore, D. F., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.0762 · Cited by 402
Lozanski, G., Heerema, N. A., Flinn, I. W., Smith, L., Harbison, J., Webb, J., Moran, M., Lucas, M., Lin, T., Hackbarth, M. L., et al. (2004) · Blood · doi:10.1182/blood-2003-10-3729 · Cited by 398
Byrd, J. C., Lin, T. S., Dalton, J. T., Wu, D., Phelps, M. A., Fischer, B., Moran, M., Blum, K. A., Rovin, B., Brooker-McEldowney, M., et al. (2007) · Blood · doi:10.1182/blood-2006-05-020735 · Cited by 390
Zenz, T., Kröber, A., Scherer, K., Häbe, S., Bühler, A., Benner, A., Denzel, T., Winkler, D., Edelmann, J., Schwänen, C., et al. (2008) · Blood · doi:10.1182/blood-2008-04-154070 · Cited by 386
Self-citationGrever, M. R., Lucas, D. M., Dewald, G. W., Neuberg, D. S., Reed, J. C., Kitada, S., Flinn, I. W., Tallman, M. S., Appelbaum, F. R., Larson, R. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.3089 · Cited by 353
Ferrajoli, A., Lee, B.-N., Schlette, E. J., O'Brien, S. M., Gao, H., Wen, S., Wierda, W. G., Estrov, Z., Faderl, S., Cohen, E. N., et al. (2008) · Blood · doi:10.1182/blood-2007-12-130120 · Cited by 337
Hallek, M. J., Langenmayer, I., Nerl, C., Knauf, W. U., Dietzfelbinger, H., Adorf, D., Ostwald, M., Busch, R. M., Kuhn-Hallek, I., Thiel, E., et al. (1999) · PubMed · doi:10.1182/blood.v93.5.1732 · Cited by 233
Self-citationSorror, M. L., Maris, M. B., Sandmaier, B. M., Storer, B. E., Stuart, M. J., Hegenbart, U., Agura, E., Chauncey, T. R., Leis, J., Pulsipher, M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.569 · Cited by 230
Stilgenbauer, S., & Döhner, H. (2002) · New England Journal of Medicine · doi:10.1056/nejm200208083470619 · Cited by 216
Self-citationKeating, M. J., O'Brien, S., Kontoyiannis, D., Plunkett, W., Koller, C., Beran, M., Lerner, S., & Kantarjian, H. (2002) · Leukemia & Lymphoma · doi:10.1080/1042819021000006547 · Cited by 192
Hale, G., Rebello, P., Brettman, L. R., Fegan, C., Kennedy, B., Kimby, E., Leach, M., Lundin, J., Mellstedt, H., Moreton, P., et al. (2004) · Blood · doi:10.1182/blood-2004-02-0593 · Cited by 182
Ritgen, M., Stilgenbauer, S., von Neuhoff, N., Humpe, A., Brüggemann, M., Pott, C., Raff, T., Kröber, A., Bunjes, D., Schlenk, R., et al. (2004) · Blood · doi:10.1182/blood-2003-12-4321 · Cited by 170
Self-citationCensoring distributions as a measure of follow‐up in survival analysis
Korn, E. L. (1986) · Statistics in Medicine · doi:10.1002/sim.4780050306 · Cited by 166
Kay, N. E., O'Brien, S. M., Pettitt, A. R., & Stilgenbauer, S. (2007) · Leukemia · doi:10.1038/sj.leu.2404802 · Cited by 102
Self-citationDemko, S., Summers, J., Keegan, P., & Pazdur, R. (2008) · The Oncologist · doi:10.1634/theoncologist.2007-0218 · Cited by 97
Pettitt, A. R., Matutes, E., & Oscier, D. G. (2006) · Leukemia · doi:10.1038/sj.leu.2404265 · Cited by 84
Osuji, N., Giudice, I. D., Matutes, E., Wotherspoon, A. C., Dearden, C. E., & Catovsky, D. (2005) · PubMed · Cited by 55
Karlsson, C., Norin, S., Kimby, E. K., Sander, B., Porwit‐MacDonald, A., Nilsson, B., Johansson, E. K., Mellstedt, H., Lundin, J., & Österborg, A. (2006) · Leukemia · doi:10.1038/sj.leu.2404435 · Cited by 40
Cited by
Stilgenbauer, S., Eichhorst, B., Schetelig, J., Coutre, S., Seymour, J. F., Munir, T., Puvvada, S. D., Wendtner, C.-M., Roberts, A. W., Jurczak, W., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30019-5 · Cited by 805
Self-citationBrown, J. R., Byrd, J. C., Coutre, S. E., Benson, D. M., Flinn, I. W., Wagner-Johnston, N. D., Spurgeon, S. E., Kahl, B. S., Bello, C., Webb, H. K., et al. (2014) · Blood · doi:10.1182/blood-2013-11-535047 · Cited by 590
From pathogenesis to treatment of chronic lymphocytic leukaemia
Zenz, T., Mertens, D., Küppers, R., Döhner, H., & Stilgenbauer, S. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2764 · Cited by 553
Self-citationBöttcher, S., Ritgen, M., Fischer, K., Stilgenbauer, S., Busch, R. M., Fingerle-Rowson, G., Fink, A. M., Bühler, A., Zenz, T., Wenger, M. K., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.9348 · Cited by 460
Self-citationRossi, D., Spina, V., Deambrogi, C., Rasi, S., Laurenti, L., Stamatopoulos, K., Arcaini, L., Lucioni, M., Rocque, G. B., Xu-Monette, Z. Y., et al. (2011) · Blood · doi:10.1182/blood-2010-09-302174 · Cited by 386
Metadata
- Authors
- Stilgenbauer, S., Zenz, T., Winkler, D., Bühler, A., Schlenk, R. F., Groner, S., Busch, R., Hensel, M., Dührsen, U., Finke, J., Dreger, P., Jäger, U., Lengfelder, E., Hohloch, K., Söling, U., Schlag, R., Kneba, M., Hallek, M., & Döhner, H.
- Venue
- Journal of Clinical Oncology
- Published
- 2009-08-20
- Volume
- 27
- Issue
- 24
- Pages
- 3994-4001
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1987819921
- Cited by
- 270
- References
- 38
- FWCI
- 16.06
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.